{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:04:48Z","timestamp":1781186688975,"version":"3.54.1"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1,15]]},"DOI":"10.2146\/ajhp090360","type":"journal-article","created":{"date-parts":[[2011,1,3]],"date-time":"2011-01-03T18:23:23Z","timestamp":1294079003000},"page":"119-124","source":"Crossref","is-referenced-by-count":20,"title":["Is double coverage of gram-negative organisms necessary?"],"prefix":"10.1093","volume":"68","author":[{"given":"Sarah J.","family":"Johnson","sequence":"first","affiliation":[{"name":"Infectious Diseases, Department of Pharmaceutical Care, University of Iowa Hospitals and Clinics, Iowa City, and Assistant Professor (Clinical), College of Pharmacy, University of Iowa, Iowa City."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika J.","family":"Ernst","sequence":"additional","affiliation":[{"name":"Drug Information Service, and Associate Professor (Clinical), College of Pharmacy, University of Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin G.","family":"Moores","sequence":"additional","affiliation":[{"name":"Drug Information Service, and Associate Professor (Clinical), College of Pharmacy, University of Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041105420453600_b1-0680119","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1086\/432803","article-title":"Overview of nosocomial infections caused by gram-negative bacilli","volume":"41","author":"Gaynes","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041105420453600_b2-0680119","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1128\/AAC.49.2.760-766.2005","article-title":"Bloodstream infections caused by antibiotic resistant gram negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome","volume":"49","author":"Kang","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041105420453600_b3-0680119","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1128\/AAC.00851-07","article-title":"Health care-associated pneumonia and community acquired pneumonia: a single-center experience","volume":"51","author":"Micek","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041105420453600_b4-0680119","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1378\/chest.118.1.146","article-title":"The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting","volume":"118","author":"Ibrahim","year":"2000","journal-title":"Chest"},{"key":"key\n\t\t\t\t2019041105420453600_b5-0680119","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/377200","article-title":"Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome","volume":"37","author":"Kang","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041105420453600_b6-0680119","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ajic.2003.09.002","article-title":"National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2003, issued August 2003","volume":"31","author":"NNIS System","year":"2003","journal-title":"Am J Infect Control"},{"key":"key\n\t\t\t\t2019041105420453600_b7-0680119","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1128\/AAC.35.11.2167","article-title":"Antimicrobial agent therapy for Pseudomonas aeruginosa","volume":"35","author":"Korvick","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041105420453600_b8-0680119","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/338782","article-title":"Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?","volume":"34","author":"Livermore","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041105420453600_b9-0680119","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0002-9343(89)80611-4","article-title":"Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients","volume":"87","author":"Hilf","year":"1989","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t2019041105420453600_b10-0680119","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.41.5.1127","article-title":"Monotherapy vs beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study","volume":"41","author":"Leibovici","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041105420453600_b11-0680119","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1001\/archinte.1985.00360090089015","article-title":"Pseudomonas bacteremia. Retrospective analysis of 410 episodes","volume":"145","author":"Bodey","year":"1985","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t2019041105420453600_b12-0680119","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archinte.160.4.501","article-title":"Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes","volume":"160","author":"Chatzinikolaou","year":"2000","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t2019041105420453600_b13-0680119","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1201-9712(98)90055-8","article-title":"Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy","volume":"2","author":"Siegman-Igra","year":"1998","journal-title":"Int J Infect Dis"},{"key":"key\n\t\t\t\t2019041105420453600_b14-0680119","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1128\/AAC.47.9.2756-2764.2003","article-title":"Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia","volume":"47","author":"Chamot","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041105420453600_b15-0680119","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJM198608283150905","article-title":"A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia","volume":"315","author":"Pizzo","year":"1986","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041105420453600_b16-0680119","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/bmj.38028.520995.63","article-title":"Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials","volume":"328","author":"Paul","year":"2004","journal-title":"BMJ"},{"key":"key\n\t\t\t\t2019041105420453600_b17-0680119","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1086\/339215","article-title":"2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer","volume":"34","author":"Hughes","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041105420453600_b18-0680119","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"171","author":"American Thoracic Society, Infectious Diseases Society of America","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"(suppl)","key":"key\n\t\t\t\t2019041105420453600_b19-0680119","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1086\/499405","article-title":"Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms","volume":"42","author":"Niederman","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041105420453600_b20-0680119","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(04)01108-9","article-title":"Does combination antimicrobial therapy reduce mortality in gram-negative bacteraemia? A meta-analysis","volume":"4","author":"Safdar","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t2019041105420453600_b21-0680119","first-page":"330","article-title":"Antimicrobial combinations","volume-title":"Antibiotics in laboratory medicine","author":"Eliopoulos","year":"1996","edition":"4th ed"},{"key":"key\n\t\t\t\t2019041105420453600_b22-0680119","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1093\/jac\/dkf211","article-title":"Synergistic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs","volume":"50","author":"Fish","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041105420453600_b23-0680119","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","article-title":"Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration","volume":"155","author":"Moore","year":"1987","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019041105420453600_b24-0680119","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1128\/AAC.43.3.623","article-title":"Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram negative bacteria","volume":"43","author":"Kashuba","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041105420453600_b25-0680119","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1128\/AAC.00115-10","article-title":"Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative micro-organisms","volume":"54","author":"Martinez","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041105420453600_b26-0680119","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.4065\/80.9.1146","article-title":"Ciprofloxacin vs an aminoglycoside in combination with a b-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials","volume":"80","author":"Bliziotis","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"key\n\t\t\t\t2019041105420453600_b27-0680119","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1128\/AAC.01231-08","article-title":"B-lactam and fluoroquinolone combination antibiotic therapy for bacteremia caused by gram-negative bacilli","volume":"53","author":"Al-Hasan","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041105420453600_b28-0680119","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/520427","article-title":"Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women","volume":"29","author":"Warren","year":"1999","journal-title":"Clin Infect Dis"},{"issue":"(suppl 4)","key":"key\n\t\t\t\t2019041105420453600_b29-0680119","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1469-0691.2005.01161.x","article-title":"Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa","volume":"11","author":"Rossolini","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t2019041105420453600_b30-0680119","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ajic.2004.10.001","article-title":"National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2004, issued October 2004","volume":"32","author":"NNIS System","year":"2004","journal-title":"Am J Infect Control"},{"key":"key\n\t\t\t\t2019041105420453600_b31-0680119","article-title":"Combination therapy for P. aeruginosa: is there an added benefit?","author":"Ernst"},{"key":"key\n\t\t\t\t2019041105420453600_b32-0680119","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1378\/chest.130.3.787","article-title":"Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia","volume":"130","author":"Beardsley","year":"2006","journal-title":"Chest"},{"key":"key\n\t\t\t\t2019041105420453600_b33-0680119","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/MPH.0b013e31819daf4a","article-title":"Piperacillin\/tazobactam plus ceftazidime versus sulbactam\/ampicillin plus aztreonam as empirical therapy for fever in severely neutropenic pediatric patients","volume":"31","author":"Kobayashi","year":"2009","journal-title":"J Pediatr Hematol Oncol"},{"key":"key\n\t\t\t\t2019041105420453600_b34-0680119","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1046\/j.1442-200X.2003.01715.x","article-title":"Piperacillin plus aztreonam for treatment of neutropenic fever","volume":"45","author":"Takeuchi","year":"2003","journal-title":"Pediatr Int"},{"issue":"(suppl 1)","key":"key\n\t\t\t\t2019041105420453600_b35-0680119","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000238716","article-title":"Therapeutic efficacy of the combination of aztreonam with cefotaxime in the treatment of severe nosocomial pneumonia. Comparative study against amikacin combined with cefotaxime","volume":"35","author":"Torres","year":"1989","journal-title":"Chemotherapy"},{"key":"key\n\t\t\t\t2019041105420453600_b36-0680119","first-page":"181","article-title":"Cephalosporin therapeutics for intensive care infections","volume":"1","author":"Salacata","year":"1993","journal-title":"New Horiz"},{"key":"key\n\t\t\t\t2019041105420453600_b37-0680119","doi-asserted-by":"crossref","first-page":"650","DOI":"10.7326\/0003-4819-115-8-650","article-title":"New beta-lactamases: new problems for the internist","volume":"115","author":"Sanders","year":"1991","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019041105420453600_b38-0680119","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1086\/374243","article-title":"Empirical antibiotic choice for the seriously ill patient: are minimization of selection of resistant organisms and maximization of individual outcome mutually exclusive?","volume":"36","author":"Paterson","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041105420453600_b39-0680119","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/510393","article-title":"Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional stewardship program to enhance antimicrobial stewardship","volume":"44","author":"Dellit","year":"2007","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041105420453600_b40-0680119","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1128\/AAC.43.6.1379","article-title":"Emergence of antibiotic resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents","volume":"43","author":"Carmeli","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041105420453600_b41-0680119","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1086\/324346","article-title":"Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates","volume":"33","author":"El Amari","year":"2001","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041105420453600_b42-0680119","article-title":"Prevention of emergence of resistance in Pseudomonas aeruginosa infections through pharmacodynamic dosing and combination chemotherapy","author":"Drusano"},{"key":"key\n\t\t\t\t2019041105420453600_b43-0680119","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3201\/eid1205.051064","article-title":"Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996\u20132003","volume":"12","author":"McDonald","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"key\n\t\t\t\t2019041105420453600_b44-0680119","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1503\/cmaj.1041104","article-title":"Clostridium difficile associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity","volume":"171","author":"Pepin","year":"2004","journal-title":"CMAJ"},{"key":"key\n\t\t\t\t2019041105420453600_b45-0680119","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1001\/jama.1994.03510480037031","article-title":"A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease","volume":"271","author":"McFarland","year":"1994","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041105420453600_b46-0680119","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1503\/cmaj.1040876","article-title":"Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies","volume":"171","author":"Dial","year":"2004","journal-title":"CMAJ"},{"key":"key\n\t\t\t\t2019041105420453600_b47-0680119","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1086\/496986","article-title":"Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile associated diarrhea","volume":"41","author":"Pepin","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041105420453600_b48-0680119","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa051639","article-title":"A predominantly clonal multi institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality","volume":"353","author":"Loo","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041105420453600_b49-0680119","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1086\/382084","article-title":"Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem","volume":"38","author":"Gerding","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041105420453600_b50-0680119","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1128\/CMR.00029-06","article-title":"Epidemiology of invasive candidiasis: a persistent public health problem","volume":"20","author":"Pfaller","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t2019041105420453600_b51-0680119","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1086\/378745","article-title":"Attributable mortality of nosocomial candidemia, revisited","volume":"37","author":"Gudlaugsson","year":"2003","journal-title":"Clin Infect Dis"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/68\/2\/119\/28348722\/ajhp0119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T10:17:09Z","timestamp":1559902629000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/68\/2\/119\/5129597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,15]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,1,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp090360","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,1,15]]},"published":{"date-parts":[[2011,1,15]]}}}